We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Department of Psychiatry, Wan Fang Hospital and School of Medicine, Taipei Medical University, Taipei, Taiwan
Winston W. Shen
Affiliation:
Department of Psychiatry, Wan Fang Hospital and School of Medicine, Taipei Medical University, Taipei, Taiwan
Mong-Liang Lu*
Affiliation:
Department of Psychiatry, Wan Fang Hospital and School of Medicine, Taipei Medical University, Taipei, Taiwan
*
Dr Mong-Liang Lu Department of Psychiatry, Wan Fang Hospital, No. 111, Sec. 3, Hsin-Long Rd, Taipei 116, Taiwan. Tel: +886 2 29307930; Fax: +886 2 29302448; E-mail: [email protected]
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Margolese, HC,
Chouinard, G,
Kolivakis, TT,
Beauclair, L,
Miller, R,
Annable, L.Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia.Can J Psychiatry2005;50:703–714.
CrossRefGoogle ScholarPubMed
3
Tarsy, D,
Baldessarini, RJ.Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?Mov Disord2006;21:589–598.
CrossRefGoogle ScholarPubMed
4
Correll, CU,
Leucht, S,
Kane, JM.Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.Am J Psychiatry2004;161:414–425.
CrossRefGoogle ScholarPubMed
Shapiro, DA,
Renock, S,
Arrington, Eet al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.Neuropsychopharmacology2003;28:1400–1411.
CrossRefGoogle ScholarPubMed
7
Hirose, T,
Uwahodo, Y,
Yamada, Set al.Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.J Psychopharmacol2004;18:375–383.
CrossRefGoogle Scholar
8
Inoue, A,
Miki, S,
Seto, Met al.Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.Eur J Pharmacol1997;321:105–111.
CrossRefGoogle Scholar
Hettema, JM,
Ross, DE.A case of aripiprazole-related tardive akathisia and its treatment with ropinirole.
J Clin Psychiatry2007;68:1814–1815.
CrossRefGoogle ScholarPubMed
11
Rizos, E,
Douzenis, A,
Gournellis, R,
Christodoulou, C,
Lykouras, LP.Tardive dyskinesia in a patient treated with quetiapine.World J Biol Psychiatry2007;8:1–4.
Google Scholar
12
Lykouras, L,
Rizos, E,
Gournellis, R.Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics.Prog Neuropsychopharmacol Biol Psychiatry2007;31:1535–1536.
CrossRefGoogle ScholarPubMed
13
Kantrowitz, JT,
Srihari, VH,
Tek, C.Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.J Clin Psychopharmacol2007;27:525–526.
CrossRefGoogle ScholarPubMed
14
Grant, MJ,
Baldessarini, RJ.Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Ann Pharmacother2005;39:1953.
CrossRefGoogle ScholarPubMed
15
Sharma, A,
Ramaswamy, S,
Dewan, VK.Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole.Prim Care Companion J Clin Psychiatry2005;7:36.
CrossRefGoogle ScholarPubMed
16
Witschy, JK,
Winter, AS.Improvement in tardive dyskinesia with aripiprazole use.Can J Psychiatry2005;50:188.
CrossRefGoogle ScholarPubMed
17
Karabulut, V,
Gonenli, S,
Yumrukcal, H,
Bakım, B,
Karamustafalıoglu, O.Aripiprazole improves neuroleptic-associated tardive dyskinesia, but it does not meliorate psychotic symptoms.Prog Neuropsychopharmacol Biol Psychiatry2008;32:1342–1343.
Google Scholar
18
Caykoylu, A,
Ekinci, O,
Yilmaz, E.Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.Prog Neuropsychopharmacol Biol Psychiatry2009;33:571–572.
CrossRefGoogle ScholarPubMed
19
Duggal, HS.Aripiprazole-induced improvement in tardive dyskinesia.Can J Psychiatry2003;48:771–772.
CrossRefGoogle ScholarPubMed
20
Miller del, D,
Eudicone, JM,
Pikalov, A,
Kim, E.Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
J Clin Psychiatry2007;68:1901–1906.
CrossRefGoogle Scholar